Traders should expect delisting from Nasdaq and cessation of public trading. Any remaining liquidity may shift to OTC markets, but with minimal trading volume expected.
Price Chart
Executive Summary
RAPT Therapeutics has filed Form 15 to terminate its SEC registration and suspend reporting obligations following its acquisition by GlaxoSmithKline. The company is now a wholly owned subsidiary of GSK, resulting in only one holder of record and effectively going private.
Key Facts
- RAPT Therapeutics filed Form 15 to terminate its registration under Section 12(g) of the Exchange Act
- The deregistration follows a merger with Redrose Acquisition Co., a subsidiary of GlaxoSmithKline LLC
- As of the filing date, there is approximately one holder of record
- The merger was executed pursuant to an agreement dated January 19, 2026
- RAPT is now a wholly owned subsidiary of GlaxoSmithKline
Financial Impact
Company is no longer publicly traded; shareholders were likely paid in the acquisition (exact terms not disclosed here)
Risk Factors
- Loss of liquidity for former shareholders
- No further public financial disclosures will be made
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (Primary) | 0001193125-26-112753 |
| Document: 0001193125-26-112753-index-headers.html | 0001193125-26-112753 |
| Document: 0001193125-26-112753-index.html | 0001193125-26-112753 |
| Document: 0001193125-26-112753.txt | 0001193125-26-112753 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access